Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

By C. J. Denman, V. Senyukov, S. Somanchi, P. Phatarpekar, L. Kopp, J. Johnson, Harjeet Singh, Lenka V. Hurton, S. Maiti, M. H. Huls and 3 more. PLoS ONE, 2012

636 citations recorded by the source corpus.

NK cells have therapeutic potential for a wide variety of human malignancies. However, because NK cells expand poorly in vitro, have limited life spans in vivo, and represent a small fraction of peripheral white blood cells, obtaining sufficient cell numbers is the major obstacle for NK-cell immunotherapy. Genetically-engineered artificial antigen-presenting cells (aAPCs) expressing membrane-bound IL-15 (mbIL15) have been used to propagate clinical-grade NK cells for human trials of adoptive immunotherapy, but ex vivo proliferation has been limited by telomere shortening. We developed K562-based aAPCs with membrane-bound IL-21 (mbIL21) and assessed their ability to support human NK-cell proliferation. In contrast to mbIL15, mbIL21-expressing aAPCs promoted log-phase NK cell expansion without evidence of senescence for up to 6 weeks of culture. By day 21, parallel expansion of NK cells from 22 donors demonstrated a mean 47,967-fold expansion (median 31,747) when co-cultured with aAPCs expressing mbIL21 compared to 825-fold expansion (median 325) with mbIL15. Despite the significant increase in proliferation, mbIL21-expanded NK cells also showed a significant increase in telomere length compared to freshly obtained NK cells, suggesting a possible mechanism for their sustained proliferation. NK cells expanded with mbIL21 were similar in phenotype and cytotoxicity to those expanded with mbIL15, with retained donor KIR repertoires and high expression of NCRs, CD16, and NKG2D, but had superior cytokine secretion. The mbIL21-expanded NK cells showed increased transcription of the activating receptor CD160, but otherwise had remarkably similar mRNA expression profiles of the 96 genes assessed. mbIL21-expanded NK cells had significant cytotoxicity against all tumor cell lines tested, retained responsiveness to inhibitory KIR ligands, and demonstrated enhanced killing via antibody-dependent cell cytotoxicity. Thus, aAPCs expressing mbIL21 promote improved proliferation of human NK cells with longer telomeres and less senescence, supporting their clinical use in propagating NK cells for adoptive immunotherapy.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/21c15f30e83f2bb0747166d883b26c1c91ee91df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Han Dong
Romee Rizwan
Guozhu Xie
Yong Liang
J. D. Ham
Jianzhu Chen

Citations in the corpus

CAR-NK cells: A promising cellular immunotherapy for cancer (2020, methodology): “[88] The method has also been adapted to large-scale GMP and recently successfully used to generate large numbers of NK cells or CAR-NK cells for phase 1 and 2 clinical trials.”
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity (2017, neutral): “mbIL21 cells co-express CD64/FcγRI, CD86/B7-2, CD137L/ 4-1BBL, truncated CD19, and membrane-bound IL-21 was recently reported to promote peripheral blood and CB NK cell expansion (16, 22).”